Financial Performance - Total revenue for the year ended December 31, 2022, reached RMB 2,988 million, representing a year-on-year increase of 70.1%[2] - Gross profit for the same period was RMB 792.1 million, reflecting a growth of 39.0% compared to the previous year[2] - The adjusted net loss (non-IFRS) narrowed to RMB 332.8 million, a decrease of 25.0% from RMB 444.0 million in the prior year[2] - Revenue increased by 70% from RMB 1,756.7 million in 2021 to RMB 2,988 million in 2022, driven by strong growth in both hospital and pharmacy solutions[21] - The net loss for the year decreased by 59.3% from RMB 4,153.2 million for the year ended December 31, 2021, to RMB 1,692.2 million for the year ended December 31, 2022, driven by significant revenue increase and changes in the fair value of financial liabilities[32] - The company reported a total comprehensive loss of RMB 2,158,772 thousand for the year, compared to RMB 4,021,261 thousand in 2021, showing an improvement in overall financial performance[54] Revenue Segments - The subscription solutions segment generated revenue of RMB 594.5 million, up 31.5% from RMB 452.0 million in the previous year[2] - The value-added solutions segment saw revenue growth of 88.4%, reaching RMB 2,205.8 million compared to RMB 1,170.7 million in the prior year[2] - The revenue from in-hospital solutions was RMB 2,184.5 million, a 71.6% increase from RMB 1,272.7 million in the previous year[10] - The revenue from pharmacy solutions was RMB 615.8 million, a 76% increase from RMB 350.0 million in the previous year[13] - The hospital solutions segment generated RMB 1,645,086 thousand in revenue for 2022, up from RMB 869,780 thousand in 2021, reflecting an increase of about 89.0%[64] - The pharmacy solutions segment's value-added solutions revenue rose to RMB 560,668 thousand in 2022, compared to RMB 300,961 thousand in 2021, marking an increase of approximately 86.0%[64] Customer and Market Expansion - The company installed its SaaS product, Zhiyun Yihui, in approximately 2,567 hospitals, including 714 tertiary public hospitals and 761 secondary public hospitals, by December 31, 2022[8] - As of December 31, 2022, the company had 26 paid pharmaceutical clients, a 73% increase from December 31, 2021[9] - The number of hospitals purchasing value-added solutions directly or indirectly reached 2,818, a 34% increase from the previous year[10] - The company's overall customer retention rate was 87%, with a retention rate of 95% for hospitals using the SaaS system[10] - The number of pharmacies using the company's SaaS system reached over 193,300, covering more than 33% of pharmacies in China[12] - The number of registered users reached approximately 28.5 million, with over 95% of new users acquired through organic channels[14] Operational Efficiency - The adjusted net loss margin (non-IFRS) improved to negative 11.1% due to significant business growth and operational leverage[7] - The ratio of sales and marketing expenses to revenue decreased from 41.5% for the year ended December 31, 2021, to 29.2% for the year ended December 31, 2022, indicating higher operational leverage and customer retention[25] - The average annual revenue per paid hospital for value-added solutions was RMB 584, a 41% increase from RMB 414 in the previous year[10] - Sales costs increased by 85% from RMB 1,186.7 million in 2021 to RMB 2,195.9 million in 2022, reflecting rapid business growth[22] Investments and Future Plans - The company plans to continue expanding its hospital and pharmacy networks, investing in product and technology innovation, and pursuing strategic partnerships and acquisitions[20] - The company aims to enhance its value proposition and hospital network through investments in SaaS capabilities and medical expertise[20] - The company plans to meet its liquidity needs through operating cash flows and capital raised from the market, with no significant external financing planned[36] - The company expects to recognize future revenue of RMB 69,157 thousand from existing contracts in the next 1 to 2 years[66] Governance and Compliance - The company has established an audit committee to oversee financial reporting and compliance, enhancing governance and transparency[46] - The company was included in the Hang Seng Index on February 24, 2023, and joined the Stock Connect program on March 13, 2023[17] - The company did not recommend a final dividend for the year ended December 31, 2022, reflecting a focus on reinvestment[51] Financial Position - As of December 31, 2022, the company's cash and cash equivalents were RMB 249.7 million, down from RMB 1,090.6 million as of December 31, 2021[36] - The company's bank and other loans amounted to RMB 192.5 million as of December 31, 2022, compared to RMB 114.4 million as of December 31, 2021[36] - The debt-to-asset ratio was 33.6% as of December 31, 2022, an increase from 30.1% as of December 31, 2021[38] - The company had total non-current assets of RMB 585,966 thousand, a substantial increase from RMB 226,421 thousand in 2021, primarily due to investments in property, plant, and equipment[55] - The company has a total net asset value of RMB 1,881,375 thousand as of December 31, 2022, compared to a negative net asset value of RMB 7,155,131 thousand in 2021[57]
智云健康(09955) - 2022 - 年度业绩